Spangler et al. No increased risk of MI or stroke in denosumab vs zoledronate in 170,000 patients from Optum/MarketScan. @RheumNow #ACR22 Abstr#0575
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis - ACR Meeting Abstracts
